Experimental drug appears to slow progression of Alzheimer's disease in clinical trial but raises safety concerns
CBS 58 is your local source for the Milwaukee news, Milwaukee weather, and Milwaukee sports.
Stay updated with breaking news from Discovery Brain Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CBS 58 is your local source for the Milwaukee news, Milwaukee weather, and Milwaukee sports.
Lecanemab has become one of the first experimental dementia drugs to appear to slow the progression of cognitive decline.
Antibody therapy lecanemab removes clumps of protein called beta amyloid that builds up in brain
Lecanemab has become one of the first experimental dementia drugs to appear to slow the progression of cognitive decline.
The experimental drug lecanemab shows "potential" as an Alzheimer's disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association with